EBITDA Margin % is calculated as EBITDA divided by its Revenue. Innovent Biologics's EBITDA for the
six
months ended in Dec. 2025 was HK$326 Mil. Innovent Biologics's Revenue for the
six
months ended in Dec. 2025 was HK$7,831 Mil. Therefore, Innovent Biologics's EBITDA margin for the quarter that ended in Dec. 2025 was 4.17%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Innovent Biologics EBITDA Margin % Related Terms
Innovent Biologics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01801 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Innovent Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) has a EBITDA Margin % of 4.17% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #223 out of 939 companies in the Biotechnology industry, placing it in the top 23.7%.
Is Innovent Biologics' EBITDA Margin % too high?
Innovent Biologics' current EBITDA Margin % is 4.17%. Based on the distribution chart, Innovent Biologics ranks #223 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovent Biologics has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #223 out of 939 companies for EBITDA Margin %. This places Innovent Biologics in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current EBITDA Margin % is 4.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (HKSE:01801) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$99.69, compared to a current price of HK$87.80 — trading 11.9% below its estimated fair value. The current EBITDA Margin % is 4.17%. Innovent Biologics' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Innovent Biologics (HKSE:01801), the current EBITDA Margin % is 4.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (HKSE:01801) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of HK$87.80 is trading 11.9% below its estimated GF Value™ of HK$99.69.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for HKSE:01801:
EBITDA Margin %: 4.17%
GF Value™: HK$99.69 vs. price of HK$87.80 (11.9% below fair value)
No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
83GF Score
Get the complete analysis for HKSE:01801
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01801 has been successfully added to your 
